Replies to post #289801 on Amarin Corp Plc (AMRN)

[Hamoa]

I’ve not sold out. I’ve been adding shares since the district court decision.

The tenor and substance of this board since the decision has kept me away. I won’t offer a detailed analysis of the last brief here, but will say that I believe Singer has given Amarin it’s best chance for a reversal. My expectation is that the infamous “weighing of secondary considerations” will offer the panel non-controversial grounds for reversal that avoid the philosophical disputes among the federal circuit. That said, I don’t think that one error, in isolation, necessarily guarantees a reversal, hence the importance of Singer’s arguments in support of the other issues (e.g. >500mg, Cyclobenzaprine citation, Kurabayashi, etc). In total, Singer’s arguments should give the panel adequate confidence that reversal is warranted.

Is it possible that the panel finds that, while errors were made, they do not warrant reversal? Yes. But I would be surprised by that given the facts at hand.

I’ll add that I also believe the following:

- ROW has been significantly undervalued
- GIA in Europe is best course for maximizing shareholder value
- a decision on the briefs is a possibility
- oral arguments will provide meaningful visibility into the court’s leanings (it will be the most important and dramatic 15 minutes of Amarin’s life. Can’t wait.)

Best of luck to all.